Proposed Wyoming Pharmacy Act Rules Revisions

The Wyoming State Board of Pharmacy proposes to amend Chapters 8, 13, 17, 18, and 22 of the Wyoming Pharmacy Act Rules and Regulations in order to modernize, reorganize and simplify the Board’s Rules and Regulations.

On January 29, 2025, emergency rules were approved. Specifically, Chapter 8 Wholesale Distributor Regulations now clarify that veterinary prescription drug wholesalers may sell or deliver non-controlled substance veterinary medications to a person responsible for the control of a “livestock animal,” as that term is defined in Wyo. Stat. § 11-29-101(a)(vi), and subject to specified conditions. The Board proposes to permanently revise Chapter 8 to continue to allow this practice.

The Board also proposes to repeal Chapter 13 Non-Sterile Compounding and Chapter 17 Sterile Compounding in order to create a new Chapter 22 Compounding. The new Chapter 22 incorporates United States Pharmacopoeia (USP) chapters 795 Pharmaceutical Compounding – Nonsterile Preparations, 797 Pharmaceutical Compounding – Sterile Preparations, 800 Hazardous Drugs—Handling in Healthcare Set-tings, and 825 Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging by refer-ence as allowed by Wyo. Stat. § 33-24-127(a). The Pure Food and Drug Act of 1906 established USP as the standard of purity, strength, and quality for medications in the United States. USP is part of The Joint Commission’s survey and is recognized by the Centers for Medicare & Medicaid Services as the minimum threshold for quality that hospitals and Critical Access Hospitals (s) must meet. Additionally, more than forty-five (45) states require compliance with USP, whether through statute or rule.

The Board proposes to remove Chapter 18’s requirement that pharmacists must successfully complete a minimum of one hour of an ACPE-accredited CE program related to the use of opiate antagonists prior to prescribing. Narcan (naloxone) was first approved by the FDA in 2015 as a prescription drug and is the standard treatment for opioid overdose. Narcan (naloxone) has since been approved for over-the-counter, nonprescription, use. Additionally, Wyo. Stat. Title 35, Ch. 4, Art. 9 Emergency Administration Of Medical Treatment Act does not require pharmacists or other health care practitioners to complete additional CE prior to prescribing epinephrine auto-injectors or opiate antagonists.

As required by Wyoming Statute § 16-3-103(a)(i)(G), these rules meet minimum substantive state statutory requirements.

Chapter 8 Wholesale Distributor Regulations:

• Section 9 is revised to clarify that veterinary prescription drug wholesalers may sell or deliver non-controlled substance veterinary medications to a person responsible for the control of a livestock animal, as defined in Wyo. Stat. § 11-29-101(a)(vi) subject to certain conditions:

  • A licensed veterinarian has issued a written a prescription order in the course of an existing, valid veterinarian-client-patient relationship;

  • The prescription order becomes void after two years, unless the veterinarian specifies a shorter expiration date;

  • The veterinary prescription drug wholesale distributor shall not distribute larger quantities than the order authorizes and must sell the non-controlled substance prescription drug(s) in the original, unbroken manufacturer’s containers;

  • Records must be retained as specified.

• Sections 13 and 16 are updated to current organization standards.

Chapter 13 Non-Sterile Compounding - Repealed

Chapter 17 Sterile Compounding - Repealed

Chapter 18 Prescribing by Pharmacists

• Section 4(b) is deleted and the section is reorganized accordingly.

Chapter 22 Compounding

• A new chapter is created incorporating USP Chapters 795, 797, 800, and 825 by reference.

• The Board has determined that posting the incorporated material on the Internet would constitute a violation of federal copyright law.

• The copyrighted incorporated material will be available for public inspection and examination, but may not be copied, at the Wyoming Department of Health, 2300 Capitol Avenue, Cheyenne, Wyoming 82002, and at the Wyoming State Board of Pharmacy, 1712 Carey Avenue, Suite 200, Cheyenne, Wyoming 82002.

Requests for copies of the proposed revisions may be addressed to the Board executive director at 1712 Carey Avenue, Suite 200, Cheyenne, WY 82002. The proposed revisions are posted on the Wyoming Secretary of State and the Wyoming State Board of Pharmacy websites.

Comments may be submitted to the Board by mail using the address above or to bop@wyo.gov on or before June 13, 2025, at 5 PM MDT.